Silo Pharma Inc
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Silo Pharma's stock due to its significant potential growth.
Financial Health
Silo Pharma is generating modest revenue and cash flow, but its profitability remains uncertain.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SILO
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial milestones ahead
Clinical data and regulatory steps can materially affect valuation, though outcomes are uncertain and may require further funding.
Scientific focus
Interest in psychedelic‑inspired and CNS therapies could attract attention, but scientific and regulatory hurdles remain significant.
Speculative profile
Very small market cap and likely low liquidity mean high volatility and potential dilution — suitable only for risk‑tolerant investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
